JP Morgan Chase
BLFS icon

JP Morgan Chase’s BioLife Solutions BLFS Stock Holding History

JP Morgan Chase’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.52M Sell
230,227
-2,467
-1% -$57.7K ﹤0.01% 3200
2026
Q1 		$4.37M Sell
232,694
-10,866
-4% -$240K ﹤0.01% 3446
2025
Q4 		$5.89M Buy
243,560
+17,946
+8% +$470K ﹤0.01% 3156
2025
Q3 		$5.76M Sell
225,614
-5,984
-3% -$142K ﹤0.01% 3229
2025
Q2 		$4.99M Sell
231,598
-11,680
-5% -$263K ﹤0.01% 3175
2025
Q1 		$5.56M Sell
243,278
-10,307
-4% -$271K ﹤0.01% 3059
2024
Q4 		$6.58M Sell
253,585
-24,748
-9% -$616K ﹤0.01% 3098
2024
Q3 		$6.97M Sell
278,333
-7,402
-3% -$175K ﹤0.01% 2939
2024
Q2 		$6.12M Sell
285,735
-49,213
-15% -$955K ﹤0.01% 2879
2024
Q1 		$6.21M Sell
334,948
-19,852
-6% -$347K ﹤0.01% 2906
2023
Q4 		$5.77M Sell
354,800
-19,541
-5% -$249K ﹤0.01% 2962
2023
Q3 		$5.17M Sell
374,341
-28,896
-7% -$455K ﹤0.01% 2824
2023
Q2 		$8.91M Sell
403,237
-2,031
-0.5% -$42.8K ﹤0.01% 2385
2023
Q1 		$8.81M Buy
405,268
+1,250
+0.3% +$28.1K ﹤0.01% 2386
2022
Q4 		$7.35M Sell
404,018
-1,652
-0.4% -$34.1K ﹤0.01% 2522
2022
Q3 		$9.23M Sell
405,670
-49,179
-11% -$1.05M ﹤0.01% 2207
2022
Q2 		$6.28M Buy
454,849
+15,397
+4% +$226K ﹤0.01% 2570
2022
Q1 		$9.99M Sell
439,452
-32,123
-7% -$846K ﹤0.01% 2372
2021
Q4 		$17.6M Buy
471,575
+81,435
+21% +$3.49M ﹤0.01% 1922
2021
Q3 		$16.5M Sell
390,140
-115,546
-23% -$5.56M ﹤0.01% 1925
2021
Q2 		$22.5M Buy
505,686
+156,325
+45% +$5.51M ﹤0.01% 1738
2021
Q1 		$12.6M Buy
349,361
+126,840
+57% +$5.02M ﹤0.01% 2148
2020
Q4 		$8.88M Buy
222,521
+103,276
+87% +$3.52M ﹤0.01% 2306
2020
Q3 		$3.42M Buy
119,245
+46,474
+64% +$1M ﹤0.01% 2858
2020
Q2 		$1.19M Buy
72,771
+29,586
+69% +$408K ﹤0.01% 3412
2020
Q1 		$410K Buy
43,185
+25,494
+144% +$350K ﹤0.01% 3918
2019
Q4 		$286K Buy
17,691
+15,479
+700% +$252K ﹤0.01% 4533
2019
Q3 		$37K Buy
2,212
+379
+21% +$7.11K ﹤0.01% 5265
2019
Q2 		$30K Buy
+1,833
New +$32K ﹤0.01% 5350

Other funds holding BLFS

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase's BLFS Position: Q2 2026 in Review

JP Morgan Chase reduced its BioLife Solutions (BLFS) stake by 1.1% in Q2 2026, selling an estimated $57.7K and leaving 230,227 shares worth $6.52M. The position accounts for ﹤0.01% of the portfolio, ranked #3200.

JP Morgan Chase first reported a position in BLFS in Q2 2019 and has held it in 29 quarters since. The position peaked at $22.5M in Q2 2021. 216 funds tracked by Wall St. Rank hold BLFS as of Q2 2026.

  • JP Morgan Chase held 230,227 shares of BioLife Solutions worth $6.52M as of Q2 2026.
  • JP Morgan Chase sold 2,467 BioLife Solutions shares in Q2 2026, an estimated $57.7K.
  • BioLife Solutions made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3200 holding.
  • JP Morgan Chase first reported a position in BioLife Solutions in Q2 2019 and has held it in 29 quarters since.
  • JP Morgan Chase's BioLife Solutions position peaked at $22.5M in Q2 2021.
  • 216 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.